CD274 and neoplasm: In addition to PD-L1 expression, metrics such as TMB, mismatch repair defects, microsatellite instability, tumor-infiltrating lymphocytes, and intestinal microbiota have demonstrated unique value in the prediction of efficacy and prognostic assessment of immunotherapy.